BioRestorative Therapies (NASDAQ: BRTX) announced the addition of serial regenerative medicine entrepreneur, company builder, and leader, Sandy Lipkins, to focus on technology commercialization and business development, effective June 9, 2025.
Mr. Lipkins will lead sourcing, structuring, negotiating and executing strategic alliances and licensing/co-development agreements for BioRestorative—both domestically and internationally—as well as provide new product and sales expertise to Biorestorative.
Mr. Lipkins has an accomplished record of business development success within the healthcare industry. With more than 30 years of venture capital, finance, and sales experience—with deep expertise in the anti-aging and wellness sectors—his extensive work and network in stem cells, regenerative medicine, and tissue banking have helped drive the development of a number of cutting-edge therapies. In addition, Mr. Lipkin’s executive experience in scaling, compounding and biologics manufacturing, as well as his proven ability to expand market reach, has been pivotal to company growth. Passionate about promoting anti-aging, healthy lifestyle, and bringing cutting-edge regenerative medicine to the critical masses, domestically and internationally, Mr. Lipkins is credited with taking companies from incubation, to revenue generation and growth, to readying for sale or other liquidity events.
In a statement, Lance Alstodt, CEO of BioRestorative, said, “We are absolutely thrilled to welcome Sandy to BioRestorative Therapies. Sandy brings a powerful blend of venture capital expertise, entrepreneurial drive, and a deep commitment to the anti-aging and regenerative medicine space. His proven track record in building and scaling companies aligns perfectly with our mission. With his experience and expertise, we see tremendous potential for significant value creation as we advance our clinical pipeline and expand our commercial BioCosmeceuticals platform. I am confident Sandy will play a key role in driving our next phase of growth and innovation.”
Mr. Lipkins commented, “I am excited to join BRTX at such a pivotal time. The company’s dedication to cutting-edge science in both clinical development and consumer wellness is inspiring, and I see tremendous opportunity to build something truly impactful here. With a strong foundation already in place, I look forward to helping accelerate growth, expand the Biocosmeceuticals platform, and bring transformative regenerative solutions to market — both at home in the U.S. and abroad in key international markets.”
